RELMADA THERAPEUTICS, INC. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Sergio Traversa (CEO) and Maged Shenouda (CFO) certified on August 6, 2026 that the Q2 2026 10-Q for the period ended June 30, 2026 complies with SEC requirements and fairly presents the company's financial condition. Both officers affirmed disclosure controls, internal controls over financial reporting, and absence of material fraud or control deficiencies. These are standard Sarbanes-Oxley Sections 302 and 906 certifications with no disclosed material weaknesses or fraud.
Why this rating
Routine quarterly certification; boilerplate SOX compliance filing with no material findings disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.